Trade Name (Agent): Talquetamab
Sponsor: Janssen Pharmaceuticals Inc.
Date of BT Designation Disclosure: 6/29/2022
Indication: Treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Category: Cancer